IL253346A0 - Modulation of apocii (apolipoprotein c-iii) expression in lipodystrophy populations - Google Patents
Modulation of apocii (apolipoprotein c-iii) expression in lipodystrophy populationsInfo
- Publication number
- IL253346A0 IL253346A0 IL253346A IL25334617A IL253346A0 IL 253346 A0 IL253346 A0 IL 253346A0 IL 253346 A IL253346 A IL 253346A IL 25334617 A IL25334617 A IL 25334617A IL 253346 A0 IL253346 A0 IL 253346A0
- Authority
- IL
- Israel
- Prior art keywords
- apociii
- lipodystrophy
- apolipoprotein
- populations
- modulation
- Prior art date
Links
- 102000030169 Apolipoprotein C-III Human genes 0.000 title 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 title 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 title 1
- 208000006132 lipodystrophy Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562126439P | 2015-02-27 | 2015-02-27 | |
| PCT/US2016/019728 WO2016138355A1 (en) | 2015-02-27 | 2016-02-26 | Modulation of apolipoprotein c-iii (apociii) expression in lipodystrophy populations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL253346A0 true IL253346A0 (en) | 2017-09-28 |
Family
ID=56789093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL253346A IL253346A0 (en) | 2015-02-27 | 2017-07-06 | Modulation of apocii (apolipoprotein c-iii) expression in lipodystrophy populations |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180245076A1 (enExample) |
| EP (1) | EP3270931A4 (enExample) |
| JP (1) | JP2018511555A (enExample) |
| KR (1) | KR20170122769A (enExample) |
| CN (1) | CN107405358A (enExample) |
| AU (1) | AU2016222548A1 (enExample) |
| BR (1) | BR112017015307A2 (enExample) |
| CA (1) | CA2977971A1 (enExample) |
| HK (1) | HK1248522A1 (enExample) |
| IL (1) | IL253346A0 (enExample) |
| MX (1) | MX2017011009A (enExample) |
| RU (1) | RU2737719C2 (enExample) |
| WO (1) | WO2016138355A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019002818A (es) * | 2016-09-12 | 2019-08-29 | Aegerion Pharmaceuticals Inc | Metodos para detectar anticuerpos neutralizantes anti-leptina. |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| WO2022072244A1 (en) * | 2020-10-02 | 2022-04-07 | Ionis Pharmaceuticals, Inc. | Methods for reducing apociii expression |
| JP2024525800A (ja) * | 2021-07-16 | 2024-07-12 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598227B2 (en) * | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| PL2670486T3 (pl) * | 2011-01-31 | 2016-08-31 | Cadila Healthcare Ltd | Leczenie lipodystrofii |
| UA115309C2 (uk) * | 2011-04-27 | 2017-10-25 | Іоніс Фармасьютікалз, Інк. | Модуляція експресії аполіпопротеїну ciii (apociii) |
| DK2956176T3 (en) * | 2013-02-14 | 2018-08-27 | Ionis Pharmaceuticals Inc | MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS |
| US9909124B2 (en) * | 2013-06-21 | 2018-03-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile |
| US20150045431A1 (en) * | 2013-08-06 | 2015-02-12 | Amarin Pharmaceuticals Ireland Limited | Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy |
-
2016
- 2016-02-26 KR KR1020177025758A patent/KR20170122769A/ko not_active Ceased
- 2016-02-26 US US15/553,946 patent/US20180245076A1/en not_active Abandoned
- 2016-02-26 AU AU2016222548A patent/AU2016222548A1/en not_active Abandoned
- 2016-02-26 BR BR112017015307A patent/BR112017015307A2/pt not_active Application Discontinuation
- 2016-02-26 HK HK18107740.8A patent/HK1248522A1/zh unknown
- 2016-02-26 CN CN201680009110.1A patent/CN107405358A/zh active Pending
- 2016-02-26 RU RU2017133142A patent/RU2737719C2/ru active
- 2016-02-26 JP JP2017538667A patent/JP2018511555A/ja active Pending
- 2016-02-26 CA CA2977971A patent/CA2977971A1/en not_active Abandoned
- 2016-02-26 MX MX2017011009A patent/MX2017011009A/es unknown
- 2016-02-26 EP EP16756424.4A patent/EP3270931A4/en not_active Withdrawn
- 2016-02-26 WO PCT/US2016/019728 patent/WO2016138355A1/en not_active Ceased
-
2017
- 2017-07-06 IL IL253346A patent/IL253346A0/en unknown
-
2019
- 2019-07-31 US US16/528,387 patent/US20200095581A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017133142A3 (enExample) | 2019-08-12 |
| AU2016222548A1 (en) | 2017-07-27 |
| US20180245076A1 (en) | 2018-08-30 |
| EP3270931A1 (en) | 2018-01-24 |
| CN107405358A (zh) | 2017-11-28 |
| RU2017133142A (ru) | 2019-03-28 |
| EP3270931A4 (en) | 2018-10-03 |
| JP2018511555A (ja) | 2018-04-26 |
| US20200095581A1 (en) | 2020-03-26 |
| HK1248522A1 (zh) | 2018-10-19 |
| MX2017011009A (es) | 2017-10-20 |
| KR20170122769A (ko) | 2017-11-06 |
| BR112017015307A2 (pt) | 2018-01-16 |
| CA2977971A1 (en) | 2016-09-01 |
| RU2737719C2 (ru) | 2020-12-02 |
| WO2016138355A1 (en) | 2016-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273312A (en) | COMPOSITIONS AND METHODS FOR MODULATION OF APOLIPOPROTEIN C–III EXPRESSION | |
| IL275246A (en) | Modulation of apolipoprotein C–III (APOCIII) expression in populations with lipoprotein lipase deficiency (LPLD) | |
| PL3320395T3 (pl) | Kompozytowe wyświetlacze elektroforetyczne | |
| GB201414589D0 (en) | Ballast circuit | |
| PL3351072T3 (pl) | Falownik do przekształcania napięcia stałego na napięcie przemienne | |
| SI3669886T1 (sl) | Kostne morfogenetične beljakovine | |
| EP3345459A4 (en) | ANALOGIC AC CIRCUIT WITH VARIABLE INTENSITY | |
| PL3226340T3 (pl) | Roztwór elektrolityczny zawierający magnez | |
| GB201509263D0 (en) | Smart lighting | |
| GB201506757D0 (en) | Cosmetic | |
| PL3150859T3 (pl) | Pompa elektryczna | |
| PL3102130T3 (pl) | Zespół śruby kostnej | |
| IL253346A0 (en) | Modulation of apocii (apolipoprotein c-iii) expression in lipodystrophy populations | |
| EP3329743A4 (en) | Direct ac driving circuit and luminaire | |
| ZA201708509B (en) | Electrical drive unit | |
| GB201508474D0 (en) | Improvements in or relating to field devices | |
| PL3160023T3 (pl) | Pompa lutownicza | |
| GB2550661B (en) | Electrical load ballasting | |
| GB201615397D0 (en) | Electric lamp circuits | |
| GB2544782B (en) | Solution | |
| GB201611586D0 (en) | Mediated reality | |
| GB2523197B (en) | Electrical load ballasting | |
| TWM490296U (en) | Medical auxiliary lighting | |
| ES1210613Y (es) | Mejoras en o relacionadas con aparatos de alumbrado eléctrico | |
| GB2537608B (en) | Improvements in or relating to voltage source converters |